Skip to main content
Springer Nature Link
Log in

Epstein–Barr Virus-Associated Post-transplant Lymphoproliferative Disease

  • Chapter
  • First Online:
Viruses and Human Cancer

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 217))

Abstract

Epstein–Barr virus (EBV) is associated with a variety of malignancies including post-transplant lymphoproliferative disease (PTLD). These include B and T cell lymphomas, epithelial, and mesenchymal tumors. The virus is ubiquitous, transmitted in saliva, and not usually associated with the development of malignancy. PTLD is usually associated with EBV when it occurs soon after the transplant. Measurement of viral DNA in blood, especially plasma, may be useful in the diagnosis of PTLD. Treatment approaches include withdrawal of immunosuppression, monoclonal antibodies or antibody conjugates, cytotoxic chemotherapy, and a variety of virus-specific treatments such as adoptive cellular therapy with EBV-specific T cells. Approaches to prevention include selection of immunosuppressive regimens that minimize the risk. In the future, EBV vaccines may be available for potential transplant recipients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (Canada)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (Canada)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (Canada)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (Canada)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  • Al Hamed R, Bazarbachi AH, Mohty M (2019) Epstein-barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities. Bone Marrow Transplant 1–15

    Google Scholar 

  • Ambinder RF, Cesarman E (2007) Clinical and pathological aspects of EBV and KSHV infection. In: Arvin A, Campadelli-Fiume G, Moore PS (eds.) Human herpesviruses biology, therapy, and immunoprophylaxis, pp. 885–914. New York, Cambridge University Press

    Google Scholar 

  • Ambinder RF, Mann RB (1994) Detection and characterization of epstein-barr virus in clinical specimens. Am J Pathol 145(2):239–252

    PubMed  PubMed Central  CAS  Google Scholar 

  • Apcher S, Daskalogianni C, Manoury B, Fåhraeus R (2010) Epstein barr virus-encoded EBNA1 interference with MHC class I antigen presentation reveals a close correlation between mRNA translation initiation and antigen presentation. PLoS Pathogens 6(10)

    Google Scholar 

  • Balfour HH Jr, Verghese P (2013) Primary epstein-barr virus infection: impact of age at acquisition, coinfection, and viral load. J Infect Dis 207(12):1787–1789

    Article  Google Scholar 

  • Balfour HH, Schmeling DO, Grimm-Geris JM (2019) The promise of a prophylactic epstein–barr virus vaccine. Pediatric Res 1–9

    Google Scholar 

  • Bolanos-Meade J, Fuchs EJ, Luznik L, Lanzkron SM, Gamper CJ, Jones RJ, Brodsky RA (2012) HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood 120(22):4285–4291

    Article  CAS  Google Scholar 

  • Brunstein CG, Weisdorf DJ, DeFor T, Barker JN, Tolar J, van Burik J-AH, Wagner JE (2006) Marked increased risk of epstein-barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 108(8):2874–2880

    Article  CAS  Google Scholar 

  • Burns DM, Clesham K, Hodgson YA, Fredrick L, Haughton J, Lannon M, Hussein H, Shin J-S, Hollows RJ, Robinson L (2020) Real-world outcomes with rituximab-based therapy for posttransplant lymphoproliferative disease arising after solid organ transplant. Transplantation

    Google Scholar 

  • Caillard S, Green M (2019) Prevention and treatment of EBV-related complications. Infectious diseases in solid-organ transplant recipients, pp. 81–91. Springer

    Google Scholar 

  • Caillard S, Lelong C, Pessione F, Moulin B, Group FPW (2006) Post‐transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French registry. Am J Transplant 6(11):2735–2742

    Google Scholar 

  • Chaulagain CP, Diacovo JM, Elson L, Comenzo RL, Samaras C, Anwer F, Khouri J, Landau H, Valent J (2020) Daratumumab-based regimen in treating clonal plasma cell neoplasms in solid organ transplant recipients. Clin Lymphoma Myeloma Leuk

    Google Scholar 

  • Cohen JI (2015) Epstein-barr virus vaccines. Clin Transl Immunology 4(1):e32

    Article  CAS  Google Scholar 

  • Cullis B, D’Souza R, McCullagh P, Harries S, Nicholls A, Lee R, Bingham C (2006) Sirolimus-induced remission of posttransplantation lymphoproliferative disorder. Am J Kidney Dis 47(5):e67–e72

    Article  Google Scholar 

  • Dierickx D, Habermann TM (2018) Post-transplantation lymphoproliferative disorders in adults. N Engl J Med 378(6):549–562

    Article  CAS  Google Scholar 

  • Hadinoto V, Shapiro M, Greenough TC, Sullivan JL, Luzuriaga K, Thorley-Lawson DA (2008) On the dynamics of acute EBV infection and the pathogenesis of infectious mononucleosis. Blood 111(3):1420–1427

    Article  CAS  Google Scholar 

  • Hammerschmidt W, Sugden B (2013) Replication of epstein-barr viral DNA. Cold Spring Harb Perspect Biol 5(1):a013029

    Article  CAS  Google Scholar 

  • Hui KF, Cheung AKL, Choi CK, Yeung PL, Middeldorp JM, Lung ML, Tsao SW, Chiang AKS (2016) Inhibition of class I histone deacetylases by romidepsin potently induces E pstein-B arr virus lytic cycle and mediates enhanced cell death with ganciclovir. Int J Cancer 138(1):125–136

    Article  CAS  Google Scholar 

  • Imus PH, Tsai HL, Luznik L, Fuchs EJ, Huff CA, Gladstone DE, Lowery P, Ambinder RF, Borrello IM, Swinnen LJ, Wagner-Johnston N, Gocke CB, Ali SA, Bolanos-Meade FJ, Varadhan R, Jones RJ (2019) Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70. Blood Adv 3(17):2608–2616

    Article  Google Scholar 

  • Jagadeesh D, Tsai D, Wei W, Wagner-Johnston N, Xie E, Berg S, Smith S, Koff J, Barot S, Hwang D (2019) Post-transplant lymphoproliferative disorder after solid organ transplant: survival and prognostication among 570 patients treated in the modern era. Hematol Oncol 37:159–160

    Article  Google Scholar 

  • Kanakry JA, Hegde AM, Durand CM, Massie AB, Greer AE, Ambinder RF, Valsamakis A (2016) The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases. Blood 127(16):2007–2017

    Article  CAS  Google Scholar 

  • Kanakry JA, Kasamon YL, Bolanos-Meade J, Borrello IM, Brodsky RA, Fuchs EJ, Ghosh N, Gladstone DE, Gocke CD, Huff CA, Kanakry CG, Luznik L, Matsui W, Mogri HJ, Swinnen LJ, Symons HJ, Jones RJ, Ambinder RF (2013) Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 19(10):1514–1517

    Article  Google Scholar 

  • Kasamon YL, Ambinder RF, Fuchs EJ, Zahurak M, Rosner GL, Bolaños-Meade J, Levis MJ, Gladstone DE, Huff CA, Swinnen LJ (2017) Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide. Blood Adv 1(4):288–292

    Article  CAS  Google Scholar 

  • Kasiske BL, Kukla A, Thomas D, Ives JW, Snyder JJ, Qiu Y, Peng Y, Dharnidharka VR, Israni AK (2011) Lymphoproliferative disorders after adult kidney transplant: epidemiology and comparison of registry report with claims-based diagnoses. Am J Kidney Dis 58(6):971–980

    Article  Google Scholar 

  • Kim WS, Ardeshna KM, Lin Y, Oki Y, Ruan J, Jacobsen ED, Yoon DH, Suh C, Suarez F, Porcu P (2017) Autologous EBV-specific T cells (CMD-003): early results from a multicenter, multinational phase 2 trial for treatment of EBV-associated NK/T-cell lymphoma. Blood 130(Supplement 1):4073

    Google Scholar 

  • Krown SE, M.D., Roy D, Ph.D., Lee JY, Ph.D., Dezube BJ, M.D., Reid EG, M.D., Venkataramanan R, Ph.D., Han K, Ph.D., Cesarman E, M.D., Ph.D., and Dittmer DP, Ph.D (2012) Rapamycin with antiretroviral therapy in AIDS-associated kaposi sarcoma: an AIDS malignancy consortium study. J Acquir Immune Defic Syndr 59(5): 447–454. https://doi.org/:10.1097/QAI.0b013e31823e7884. PMCID: PMC3302934. NIHMSID: NIHMS340254. PMID: 22067664

  • Landgren O, Gilbert ES, Rizzo JD, Socié G, Banks PM, Sobocinski KA, Horowitz MM, Jaffe ES, Kingma DW, Travis LB (2009) Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood, J Am Soc Hematol 113(20):4992–5001

    CAS  Google Scholar 

  • Levitskaya J, Coram M, Levitsky V, Imreh S, Steigerwald-Mullen PM, Klein G, Kurilla MG, Masucci MG (1995) Inhibition of antigen processing by the internal repeat region of the epstein-barr virus nuclear antigen-1. Nature 375(6533):685–688

    Article  CAS  Google Scholar 

  • Luskin MR, Heil DS, Tan KS, Choi S, Stadtmauer EA, Schuster SJ, Porter DL, Vonderheide RH, Bagg A, Heitjan DF (2015) The impact of EBV status on characteristics and outcomes of posttransplantation lymphoproliferative disorder. Am J Transplant 15(10):2665–2673

    Article  CAS  Google Scholar 

  • Nanmoku K, Shinzato T, Kubo T, Shimizu T, Yagisawa T (2019) Remission of epstein-barr virus-positive post-transplant lymphoproliferative disorder by conversion to everolimus in a kidney transplant recipient. Transpl Infect Dis 21(4):e13116

    Article  CAS  Google Scholar 

  • Pearse W, Pro B, Gordon LI, Karmali R, Winter JN, Ma S, Behdad A, Klein A, Petrich AM, Jovanovic B (2019) A phase I/II trial of brentuximab vedotin (BV) plus rituximab (R) as frontline therapy for patients with immunosuppression-associated CD30 + and/or EBV + lymphomas. American Society of Hematology. Washington, DC

    Google Scholar 

  • Prockop SE, Suser S, Doubrovina ES, Castro-Malaspina H, Papadopoulos EB, Sauter CS, Young JW, Szenes V, Slocum A, Baroudy K (2019) Efficacy of donor and ‘third party’(tabelecleucel) EBV-specific T cells for treatment of central nervous system (CNS) EBV-PTLD. Biol Blood Marrow Transplant 25(3):S72

    Article  Google Scholar 

  • Rowe M, Lear A, Croom-Carter D, Davies A, Rickinson A (1992) Three pathways of epstein-barr virus gene activation from EBNA1-positive latency in B lymphocytes. J Virol 66(1):122–131

    Article  CAS  Google Scholar 

  • Ru Y, Chen J, Wu D (2018) Epstein-barr virus post-transplant lymphoproliferative disease (PTLD) after hematopoietic stem cell transplantation. Eur J Haematol 101(3):283–290

    Article  CAS  Google Scholar 

  • Sampaio MS, Cho YW, Shah T, Bunnapradist S, Hutchinson IV (2012) Impact of epstein-barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients. Nephrol Dial Transplant 27(7):2971–2979

    Article  Google Scholar 

  • Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, Ranieri E, Gesualdo L, Schena FP, Grandaliano G (2005) Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med 352(13):1317–1323

    Article  CAS  Google Scholar 

  • Swerdlow S, Campo E, Harris NL, Jaffe E, Pileri S, Stein H, Thiele J, Arber D, Hasserjian R, Le Beau M (2017) WHO classification of tumours of haematopoietic and lymphoid tissues (Revised 4th edition). IARC Lyon 421

    Google Scholar 

  • Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375–2390

    Article  CAS  Google Scholar 

  • Thorley-Lawson DA (2001) Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol 1(1):75–82

    Article  CAS  Google Scholar 

  • Thorley-Lawson DA, Gross A (2004) Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 350(13):1328–1337

    Article  CAS  Google Scholar 

  • Thorley-Lawson DA, Hawkins JB, Tracy SI, Shapiro M (2013) The pathogenesis of epstein-barr virus persistent infection. Curr Opin Virol 3(3):227–232

    Article  CAS  Google Scholar 

  • Tsai D, Douglas L, Andreadis C, Vogl D, Arnoldi S, Kotloff R, Svoboda J, Bloom R, Olthoff K, Brozena S (2008) EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial. Am J Transplant 8(5):1016–1024

    Article  CAS  Google Scholar 

  • Vereide DT, Sugden B (2011) Lymphomas differ in their dependence on epstein-barr virus. Blood, J Am Soc Hematol 117(6):1977–1985

    CAS  Google Scholar 

  • Wu TC, Mann RB, Charache P, Hayward SD, Staal S, Lambe BC, Ambinder RF (1990) Detection of EBV gene expression in reed-sternberg cells of Hodgkin’s disease. Int J Cancer 46(5):801–804

    Article  CAS  Google Scholar 

  • Yang J, Tao Q, Flinn IW, Murray PG, Post LE, Ma H, Piantadosi S, Caligiuri MA, Ambinder RF (2000) Characterization of epstein-barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood 96(13):4055–4063

    Article  CAS  Google Scholar 

  • Young LS, Yap LF, Murray PG (2016) Epstein-barr virus: more than 50 years old and still providing surprises. Nat Rev Cancer 16(12):789–802

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, US

    Richard F. Ambinder

Authors
  1. Richard F. Ambinder
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard F. Ambinder .

Editor information

Editors and Affiliations

  1. School of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    T.-C. Wu

  2. Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan

    Mei-Hwei Chang

  3. Molecular Virology Section, Laboratory of Mole, National Institute of Allergy and Infect, Bethesda, MD, USA

    Kuan-Teh Jeang

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ambinder, R.F. (2021). Epstein–Barr Virus-Associated Post-transplant Lymphoproliferative Disease. In: Wu, TC., Chang, MH., Jeang, KT. (eds) Viruses and Human Cancer. Recent Results in Cancer Research, vol 217. Springer, Cham. https://doi.org/10.1007/978-3-030-57362-1_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-57362-1_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-57361-4

  • Online ISBN: 978-3-030-57362-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation